Evaluating bedaquiline as a treatment option for multidrug-resistant tuberculosis

References

• GBD_ 2017_Causes_of_Death_Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1736–1788.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet. 1997;349(9061):1269–1276.
   PubMed Web of Science ®Google Scholar
• Ritchie H, Roser M. Causes of death. ourworldInDataorg 2018 [ cited 2020 Nov 20]; Available from: https://ourworldindata.org/causes-of-death
   Google Scholar
• World_Health_Organization. Global tuberculosis report 2019. Geneva: World_Health_Organization; 2019.
   Google Scholar
• World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World_Health_Organization; 2019.
   Google Scholar
• Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10): e93–e142.
   PubMed Web of Science ®Google Scholar
• Dheda K, Gumbo T, Maartens G, et al. The lancet respiratory medicine commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respir Med. 2019;7(9): 820–826.
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Nahid P, Loddenkemper R, et al. The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis. Eur Respir J. 2016;48(4):963–971.
   PubMed Web of Science ®Google Scholar
• Dheda K, Chang KC, Guglielmetti L, et al. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Microbiol Infect. 2017;23(3):131–140.
   PubMed Web of Science ®Google Scholar
• Lange C, Aarnoutse RE, Alffenaar JWC, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(6):645–662.
   PubMed Web of Science ®Google Scholar
• Pontali E, Raviglione MC, Migliori GB. Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives. Eur Respir Rev. 2019;28(152):190035.
   PubMed Web of Science ®Google Scholar
• Caminero JA, Garcia-Basteiro AL, Rendon A, et al. The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines. Eur Respir J . 2019;54(4):1901272.
   PubMed Web of Science ®Google Scholar
• Caminero JA, Garcia-Garcia JM, Cayla JA, et al. Update of SEPAR guideline diagnosis and treatment of drug-resistant tuberculosis. Arch Bronconeumol. 2020;56(8):514–521.
   PubMed Web of Science ®Google Scholar
• World_Health_Organization. Rapid communication: key changes to treatment of drug-resistant tuberculosis. Geneva: World_Health_Organization; 2019.
   Google Scholar
• Kadura S, King N, Nakhoul M, et al. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. J Antimicrob Chemother. 2020;75(8):3.
   Web of Science ®Google Scholar
• United States Food and Drug Administration. Sirturo (bedaquiline) label; 2020 May [cited 2020 Jul; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204384s013lbl.pdf
   Google Scholar
• Worley MV, Estrada SJ. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Pharmacotherapy. 2014;34(11):1187–1197.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Sirturo: EPAR - product information; 2019 February 19. [cited 2020 Nov 15]. Available from: https://www.ema.europa.eu/documents/product-information/sirturo-epar-product-information_en.pdf
   Google Scholar
• Koul A, Vranckx L, Dendouga N, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem. 2008;283(37):25273–25280.
   PubMed Web of Science ®Google Scholar
• Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol. 2007;3(6):323–324.
   PubMed Web of Science ®Google Scholar
• Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52(8):2831–2835.
   PubMed Web of Science ®Google Scholar
• Kundu S, Biukovic G, Gruber G, et al. Bedaquiline targets the epsilon subunit of mycobacterial F-ATP synthase. Antimicrob Agents Chemother. 2016;60(11):6977–6979.
   PubMed Web of Science ®Google Scholar
• Patel P, Pawara R, Pawara K. A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity. Tuberculosis (Edinb). 2019;117:79–84.
   PubMed Web of Science ®Google Scholar
• McLeay SC, Vis P, van Heeswijk RP, et al. Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug. Antimicrob Agents Chemother. 2014;58(9):5315–5324.
   PubMed Web of Science ®Google Scholar
• Rouan MC, Lounis N, Gevers T, et al. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother. 2012;56(3):1444–1451.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The use of bedaquiline in the treatment of multi-drug resistant tuberculosis: interim policy guidance. Geneva: WHO; 2013.
   Google Scholar
• World Health Organization. Technical report on the pharmacokinetics and pharmacodynamics (PK/PD) of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2018.
   Google Scholar
• Pandie M, Wiesner L, McIlleron H, et al. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother. 2016;71(4):1037–1040.
   PubMed Web of Science ®Google Scholar
• Healan AM, Griffiss JM, Proskin HM, et al. Impact of rifabutin or rifampin on bedaquiline safety, tolerability, and pharmacokinetics assessed in a randomized clinical trial with healthy adult volunteers. Antimicrob Agents Chemother. 2018;62(1). DOI:10.1128/AAC.00855-17.
   PubMed Web of Science ®Google Scholar
• Svensson EM, Murray S, Karlsson MO, et al. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother. 2015;70(4):1106–1114.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23): 2397–2405.
   PubMed Web of Science ®Google Scholar
• Chahine EB, Karaoui LR, Mansour H. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother. 2014;48(1):107–115.
   PubMed Web of Science ®Google Scholar
• Fox GJ, Menzies DA. Review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis. Infect Dis Ther. 2013;2(2):123–144.
   PubMedGoogle Scholar
• Mase S, Chorba T, Parks S, et al. Bedaquiline for the treatment of multidrug-resistant tuberculosis in the United States. Clin Infect Dis. 2020;71(4):1010–1016.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Dahiya N. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis (Edinb). 2014;94(4):357–362.
   PubMed Web of Science ®Google Scholar
• Li Y, Sun F, Zhang W. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: promising but challenging. Drug Dev Res. 2019;80(1):98–105.
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Cao TB, Akkerman OW, et al. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. Expert Rev Clin Pharmacol. 2016;9(8):1025–1037.
   PubMed Web of Science ®Google Scholar
• Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387.
   PubMed Web of Science ®Google Scholar
• Pontali E, D’Ambrosio L, Centis R, et al. Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline. Eur Respir J. 2017;49(3):1700146.
   PubMed Web of Science ®Google Scholar
• Pontali E, Sotgiu G, D’Ambrosio L, et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J. 2016;47(2):394–402.
   PubMed Web of Science ®Google Scholar
• EUCAST. Rationale for EUCAST clinical breakpoints: bedaquiline; 2019 [cited 2020 Oct 06]. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/190704_Bedaquiline_rational_document.pdf
   Google Scholar
• Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect. 2020:15. DOI:10.1016/j.cmi.2020.06.004
   Google Scholar
• Salhotra VS, Sachdeva KS, Kshirsagar N, et al. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: an interim analysis. Indian J Tuberc. 2020;67(1):29–37.
   PubMedGoogle Scholar
• Olayanju O, Esmail A, Limberis J, et al. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. Eur Respir J. 2020;55(1):1901181.
   PubMed Web of Science ®Google Scholar
• Mpobela Agnarson A, Williams A, Kambili C, et al. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa. Expert Rev Anti Infect Ther. 2020;18(5):475–483.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kwon OJ, Kim YS, et al. Bedaquiline in multidrug-resistant tuberculosis treatment: safety and efficacy in a Korean subpopulation. Respir Investig. 2020;58(1):45–51.
   PubMed Web of Science ®Google Scholar
• Kang H, Jo KW, Jeon D, et al. Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea. Respir Med. 2020;167:105956.
   PubMed Web of Science ®Google Scholar
• Kwon YS, Jeon D, Kang H, et al. Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea. Eur Respir J. 2020;22:2003026.
   Google Scholar
• Pontali E, Sotgiu G, Tiberi S, et al. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. Eur Respir J. 2018;52(1): 1800934.
   PubMed Web of Science ®Google Scholar
• Vambe D, Kay AW, Furin J, et al. Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini. Int J Tuberc Lung Dis. 2020;24(10):1095–1102.
   PubMed Web of Science ®Google Scholar
• Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723–732.
   PubMed Web of Science ®Google Scholar
• Pym AS, Diacon AH, Tang SJ, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47(2):564–574.
   PubMed Web of Science ®Google Scholar
• Schnippel K, Ndjeka N, Maartens G, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018;6(9):699–706.
   PubMed Web of Science ®Google Scholar
• Olayanju O, Limberis J, Esmail A, et al. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J. 2018;51(5):1800544.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821–834.
   PubMed Web of Science ®Google Scholar
• Ndjeka N. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis - authors’ reply. Lancet Respir Med. 2018;6(12):e57.
   PubMed Web of Science ®Google Scholar
• Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J. 2017;50(5):1701462.
   PubMed Web of Science ®Google Scholar
• Peretokina IV, Krylova LY, Antonova OV, et al. Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates. J Infect. 2020;80(5):527–535.
   PubMed Web of Science ®Google Scholar
• Nimmo C, Millard J, Brien K, et al. Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients. Eur Respir J. 2020;55(6):1902383.
   PubMed Web of Science ®Google Scholar
• Kunkel A, Furin J, Cohen T. Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified? Lancet Infect Dis. 2017;17(12):e429–e33.
   PubMed Web of Science ®Google Scholar
• Borisov S, Danila E, Maryandyshev A, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J. 2019;54(6):1901522.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Application for the inclusion of bedaquiline in the WHO model list of essential medicines for children, as a reserve second‐line drug for the treatment of multidrug‐resistant tuberculosis (complementary lists of anti‐ tuberculosis drugs for use in adults); 2019. [cited 2020 Nov 15]. Available from: http://origin.who.int/selection_medicines/committees/expert/22/applications/s6.2.4_bedaquiline-EMLc.pdf
   Google Scholar
• European Medicines Agency. Sirturo (bedaquiline). Summary of opinion (post authorisation); 2019 December 12. [cited 2020 Jul 20]. Available from: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sirturo-ii-33-g_en.pdf
   Google Scholar
• Johnson J. Press note: U.S. FDA approves new pediatric formulation of SIRTURO® (bedaquiline) as part of combination therapy to treat children with pulmonary multidrug-resistant tuberculosis; 2020 May 27. [cited 2020 Jul 20]. Available from: https://www.jnj.com/u-s-fda-approves-new-pediatric-formulation-of-sirturoo-bedaquiline-as-part-of-combination-therapy-to-treat-children-with-pulmonary-multidrug-resistant-tuberculosis
   Google Scholar
• Masuku SD, Berhanu R, Van Rensburg C, et al. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis. Int J Tuberc Lung Dis. 2020;24(4):376–382.
   PubMed Web of Science ®Google Scholar
• Sarathy JP, Ragunathan P, Cooper CB, et al. 876 Displays bedaquiline-like mycobactericidal potency without retaining the parental drug’s uncoupler activity. Antimicrob Agents Chemother. 2020;64:2.
   Web of Science ®Google Scholar
• Sarathy JP, Ragunathan P, Shin J, et al. TBAJ-876 retains bedaquiline’s activity against subunits c and ε of Mycobacterium tuberculosis F-ATP synthase. Antimicrob Agents Chemother. 2019;63(10):e01191–19.
   PubMed Web of Science ®Google Scholar
• Nunn AJ, Rusen ID, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials. 2014;15(1):353.
   PubMedGoogle Scholar